Anti-CTLA4 Monoclonal Antibody Ipilimumab in the Treatment of Metastatic Melanoma: Recent Findings

E-ISSN： 2212-3970|3|2|105-113

ISSN： 1574-8928

Source： Recent Patents on Anti-Cancer Drug Discovery, Vol.3, Iss.2, 2008-06, pp. : 105-113

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sorafenib enhances the antitumor effects of anti-CTLA-4 antibody in a murine cancer model by inhibiting myeloid-derived suppressor cells

Oncology Reports, Vol. 33, Iss. 6, 2015-01 ,pp. : 2947-2953

Spandidos Publications

Access to resources Recommend Favorite

Realworld efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma

Oncology Letters, Vol. 11, Iss. 2, 2016-01 ,pp. : 1581-1585

Spandidos Publications

Access to resources Recommend Favorite

The Role of the CTLA4 Blockade in the Treatment of Malignant Melanoma

By Cranmer Lee Hersh Evan

Cancer Investigation, Vol. 25, Iss. 7, 2007-10 ,pp. : 613-631

Informa Healthcare

Access to resources Recommend Favorite

Severe colitis while responding to ipilimumab in metastatic melanoma

By Slingerland Marije Nortier Johan W. R. Veenendaal Roeland A. Kapiteijn Ellen

Acta Oncologica, Vol. 51, Iss. 6, 2012-07 ,pp. : 805-807

Informa Healthcare

Access to resources Recommend Favorite

Ipilimumab: showing survival benefit in metastatic melanoma

By Minchom Anna Young Kate Larkin James

Future Oncology, Vol. 7, Iss. 11, 2011-11 ,pp. : 1255-1264

Future Medicine

Access to resources Recommend Favorite